Literature DB >> 25249303

Surgical quality data and survival after pancreatic cancer resections: a comparison of results for octogenarians and younger patients.

Odo Gangl1, Uwe Fröschl, Reinhold Függer.   

Abstract

BACKGROUND: Although age is no contraindication for pancreatic cancer resections, there are conflicting reports of morbidity and mortality rates and only few data showing direct comparisons of survival for octogenarians and patients younger than 80 years.
METHODS: Comparison of complication, reintervention, reoperation, and 30-day in-hospital mortality rates, length of stay, and survival of all octogenarians and patients younger than 80 years undergoing pancreatectomy for ductal adenocarcinoma during the study period from 2001 to 2010 was done. All resectable patients with suspected ductal adenocarcinoma who deemed to be fit for surgery in an interdisciplinary assessment (anesthesiology, gastroenterology, oncology, surgery) were offered pancreatectomy. The only exceptions were Eastern Cooperative Oncology Group (ECOG) performance score 3 and 4 or advanced dementia patients. Resectability was determined according to contrast-enhanced computed tomography scans (pancreas protocol). The database was prospectively maintained. For survival analysis, a first follow-up was made on December 31, 2010, by a query of the national register of residents with retrieval of corresponding International Classification of Diseases (ICD) death diagnoses by the Austrian Institute of Statistics. For surviving octogenarians, a second follow-up was made by telephone interview on August 21, 2013.
RESULTS: We identified 9 octogenarians and 99 patients younger than 80 years. Median age in the two groups was 83 and 67 years, respectively. The predominant procedure in both groups was pylorus-preserving pancreaticoduodenectomy (55.6 and 68.7 %, respectively). Complications occurred in 33.3 and 28.3 % of patients, respectively. Reintervention, reoperation, and 30-day in-hospital mortality rates of patients younger than 80 years were 9.1, 6.1, and 5.1 %, respectively. In the octogenarian group, there were no pancreatic fistulas, one transient ischemic attack after stenting of an intraoperatively detected stenosis of the celiac trunk, one infected hematoma that was managed with intravenous antibiotics, and one wound infection. There were no reoperations or postoperative reinterventions. Median length of stay was 18 days, and postoperative 30-day mortality was nil. Median survival was comparable for both age-groups (10.5 vs. 12.1 months, respectively).
CONCLUSION: In an interdisciplinary setting, surgical quality data and survival after pancreatic cancer resections are comparable in octogenarians and patients younger than 80 years.

Entities:  

Mesh:

Year:  2014        PMID: 25249303     DOI: 10.1007/s00508-014-0603-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  12 in total

1.  The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial.

Authors:  Micheal G Sarr
Journal:  J Am Coll Surg       Date:  2003-04       Impact factor: 6.113

2.  Evolution of the Whipple procedure at the Massachusetts General Hospital.

Authors:  Carlos Fernández-del Castillo; Vicente Morales-Oyarvide; Deborah McGrath; Jennifer A Wargo; Cristina R Ferrone; Sarah P Thayer; Keith D Lillemoe; Andrew L Warshaw
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

3.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

4.  Pancreas surgery is safe for octogenarians.

Authors:  John A Stauffer; Manpreet S Grewal; J K Martin; Justin H Nguyen; Horacio J Asbun
Journal:  J Am Geriatr Soc       Date:  2011-01       Impact factor: 5.562

5.  Pancreatic surgery in the very old: face to face with a challenge of the near future.

Authors:  Orlin Belyaev; Torsten Herzog; Guelnur Kaya; Ansgar M Chromik; Kirsten Meurer; Waldemar Uhl; Christophe A Müller
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

6.  Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy.

Authors:  Ioannis Hatzaras; Carl Schmidt; Dori Klemanski; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston
Journal:  J Am Coll Surg       Date:  2011-01-12       Impact factor: 6.113

7.  The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits.

Authors:  Marcovalerio Melis; Francesca Marcon; Antonio Masi; Antonio Pinna; Umut Sarpel; George Miller; Harvey Moore; Steven Cohen; Russell Berman; H Leon Pachter; Elliot Newman
Journal:  HPB (Oxford)       Date:  2012-05-29       Impact factor: 3.647

8.  Results of pancreatic surgery in the elderly: is age a barrier?

Authors:  Melissa Oliveira-Cunha; Deep J Malde; Amer Aldouri; Gareth Morris-Stiff; Krishna V Menon; Andrew Malvern Smith
Journal:  HPB (Oxford)       Date:  2012-08-26       Impact factor: 3.647

9.  Pancreaticoduodenectomy in elderly adults: is it justified in terms of mortality, long-term morbidity, and quality of life?

Authors:  Fabian Gerstenhaber; Julie Grossman; Nir Lubezky; Eran Itzkowitz; Ido Nachmany; Ronen Sever; Menahem Ben-Haim; Richard Nakache; Joseph M Klausner; Guy Lahat
Journal:  J Am Geriatr Soc       Date:  2013-07-18       Impact factor: 5.562

10.  Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Jamie Ritchey; Andrew K Stewart; David P Winchester; Mark S Talamonti
Journal:  Cancer       Date:  2007-08-15       Impact factor: 6.860

View more
  1 in total

1.  Does Major Pancreatic Surgery Have Utility in Nonagenarians with Pancreas Cancer?

Authors:  Rebecca S Meltzer; David A Kooby; Jeffrey M Switchenko; Jashodeep Datta; Darren R Carpizo; Shishir K Maithel; Mihir M Shah
Journal:  Ann Surg Oncol       Date:  2020-11-03       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.